Macsita-MXR 100/500 Tablet is a combination oral antidiabetic medication containing Sitagliptin 100 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body's natural ability to regulate blood glucose by increasing incretin levels, which in turn stimulate insulin release and decrease glucagon secretion in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization. The synergistic effect of these two agents helps achieve better glycemic control in patients inadequately controlled on diet and exercise alone or on monotherapy. Macsita-MXR 100/500 is typically prescribed as part of a comprehensive diabetes management plan that includes lifestyle modifications such as diet and physical activity. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Regular monitoring of renal function and glycemic parameters is recommended during therapy to ensure safety and efficacy. This combination therapy offers an effective option for optimizing glycemic control in type 2 diabetes patients.